NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM

NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts: monotherapy dose escalation (Part A) and monotherapy dose expansion (Part B).

Sponsor

Celgene

Multiple Locations

International Study

---

ClinicalTrials.gov Identifier: NCT04975399

Official Title: A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-92328 in Subjects With Relapsed and/or Refractory Multiple Myeloma

First Posted : July 23, 2021

Click here to see details on ClinicalTrials.gov

---

Drug: CC-92328

---

CC-92328

(DF 3001)

NK cell engager

TriNKET

tri-specific natural killer cell engager therapy

---

The Phase 1 clinical trial for the CC-92328 TriNKET is a first-in-human study which will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). Additional information about the trial, including eligibility criteria, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04975399).

Learn more

Natural killer cell engagers in cancer immunotherapy

https://onlinelibrary.wiley.com/doi/full/10.1002/eji.202048953

---

Locations

United States, Alabama

United States, Arizona

United States, Florida

United States, Maryland

United States, New York

United States, Wisconsin

Canada, Alberta

Canada, Nova Scotia

Canada, Ontario

Canada, Quebec

Europe

Spain

Sweden